MGMT and glioblastoma: The DNA-repair enzyme MGMT conferred the major resistance to alkylating agents in glioblastoma patients[38], and epigenetic silencing of MGMT by gene promoter methylation had been widely investigated in younger glioblastoma patients.[38] However, the clinical relevance is ill-defined in older patients.[6] The present study, first of all, reports a stable presence of methylated MGMT promoter in older patient cohort, indicating a less possibility of an altered MGMT methylation pattern that contributes to the poorer prognosis of elderly glioblastoma patients.